anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Retrieval memory is supported by distinct retrieval process known as recollection and familiarity. These two process have been associated with distinct event related potentials (ERPs). At the time of retrieval, familiarity is associated with modulation of the FN400, an enhanced positivity for old items relative to new items observed from approximately 400-600ms post stimulus onset. The FN400 tends to have mid-frontal scalp distribution which can extend to left and right frontal areas and central midline regions. In contrast, recollection has been linked with modulation of positive going waveform that emerges approximately 600ms post stimulus and is typically maximal over parietal sites and referred to as late positive component (LPC). In addition, FN400 is found to increase gradually as a function of item retrieval confidence whereas LPC is limited to high confidence retrieval response.

High Definition transcranial Direct Current Stimulation (HD-tDCS ) is a non-invasive neuromodulation technique. Compared to the standard bipolar montage used by the conventional tDCS, it uses arrays of smaller, specially designed electrodes to deliver a constant and low current directly to the cortical brain areas to increase the spatial focality. Studies show that the cortical area undergoing stimulation with HD-tDCS is more restricted compared to the standard bipolar montage of conventional tDCS. Moreover, tDCS has been proposed as a therapeutic procedure in various diseases and tDCS in healthy adults have demonstrated to improve cognitive and memory performance, but information regarding the effects of HD-tDCS targeting the PCC and its impact on memory retrieval is scarce. By targeting the PCC area by HD-tDCS, we want to introduce a safer, easier-to-use and more accurate non-invasive neuromodulation procedure. The dysfunctions of posterior cingulate cortex hav been linked to a range of psychiatric and neurological condition such as Alzheimer's disease, schizophrenia, autism, depression and attention deficit hyperactivity disorder, as well as aging. It shows increased activity when subject retrieve autobiographical memories suggests its internal orientated function. PET and ERP combined studies have shown greater blood flow medial temporal lobe with a brief late positive ERP component in PCC. Therefore, in this study we aim to understand whether HD-tDCS targeting the PCC can modulate the late positive ERP component.
The objective of the VIRCHILLD project is to identify age-related modifications of the bronchial epithelium physiology able to explain differences in the response to respiratory viruses. Several epidemiological and cell-based data have demonstrated that respiratory virus infections differentially affect children, adults or the elderly populations. Perhaps, this difference has been put most notably into the spotlight by the current worldwide pandemic of SARS-CoV-2 with a large part of the deaths occurring in the elderly population whereas very few deaths amongst children have been recorded. According to some studies, this could be linked to a decreased transmission and/or viral load with SARS-CoV-2 in children compared to adults and elderly. What is less in the public eye is the observation that other major respiratory virus targeting the bronchial epithelium such as rhinovirus and adenovirus cause important clinical feature in children and have a much lower incidence in adults and the elderly populations, which is the opposite to the situation with SARS-CoV-2. Based on this remarkable discrepancy between respiratory viruses the investigators hypothesize that intrinsic age-controlled properties of the respiratory epithelium under resting physiological conditions determines virus susceptibility and virus propagation. Such hypothesis is supported by the literature and our own strong preliminary data. A highly complementing consortium composed of experts in lung physiology, pulmonary transcriptomic, respiratory viruses and ultrastructure analysis will address the question. The investigators will use three major respiratory pathogens (AdV, RV and SARS-CoV-2) to infect reconstituted fully functional respiratory epithelium obtained from children, adults and elderly and study parameters of virus infection and epithelial response. This project should highlight specific therapeutic targets against respiratory viruses with a high prevalence in children such as rhinovirus and adenoviruses to increase the therapeutic arsenal of clinician against those infections.
Disclosed is a method for characterising tinnitus in a subject. The method comprises receiving data comprising cortical activity data indicative of cortical activity in one or more regions of the subject's brain, and cardiac activity data indicative of cardiac activity in the subject, at a processor device. The cortical activity data is derived from one or more functional near-infrared spectroscopy (fNIRS) signals. The received data is processed using the processor device by inputting feature values into a model, where the feature values include one or more features of the cortical activity data and one or more features of the cardiac activity data. The model is configured to provide one or more classification results based on the feature values, the classification results being indicative of at least one characteristic of tinnitus in the subject. Also disclosed is a system for applying the disclosed method.
The incidence of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) infection is increasing and is associated with vancomycin treatment failures. However, studies investigating the risk factors for treatment failure in hVISA infection are limited. Patients with hVISA bacteremia treated with vancomycin over 7 days between August 2008 and June 2020 were enrolled in this study. Clinical and microbiological characteristics were compared between vancomycin treatment failure and success groups to identify the risk factors for vancomycin treatment failure. Among the 180 patients with hVISA bacteremia, 102 patients treated with vancomycin over 7 days were included. Vancomycin treatment failed in 80 (78%) patients. Patients in the vancomycin treatment failure group were older (P < 0.001) and more frequently had solid cancer (P = 0.04) than those in the vancomycin treatment success group. Solid organ transplantation (SOT) was more frequent (P < 0.001) in the vancomycin treatment success group. The Charlson comorbidity index (P = 0.01) and Acute Physiology and Chronic Health Evaluation II scores (P < 0.001) were higher in the vancomycin treatment failure group. In multivariate analysis, independent risk factors for vancomycin treatment failure were old age and severity of bacteremia. SOT and vancomycin minimal inhibitory concentration (MIC) ≤ 1.0 mg/L using the broth microdilution (BMD) method were associated with successful vancomycin treatment. Old age and infection severity were independent risk factors for vancomycin treatment failure. Vancomycin MIC using the BMD method is an important risk factor for vancomycin treatment failure, and its use should be considered in hVISA bacteremia.IMPORTANCEIn this study, we assessed the clinical and microbiological characteristics of heterogeneous vancomycin-intermediated Staphylococcus aureus (hVISA) bacteremia and identified risk factors for vancomycin treatment failure. We found that advanced age and severity of infection were independent risk factors for vancomycin treatment failure. On the other hand, solid organ transplantation and a low vancomycin minimal inhibitory concentration were associated with successful vancomycin treatment. This study highlights the importance of vancomycin minimal inhibitory concentration in hVISA bacteremia.
Group exposed to direct current application using an acupuncture needle with intensities in microamps (μA) in MTrP of upper trapezius muscle. Acupuncture needle correspond to negative electrode or cathode. This group was also be treated with conventional ultrasound (US) before MEP application. US treatments parameters will include; 1MHz, 1.5W/cm2, 5cm2 ERA, 100% duty cycle and 15 minutes treatment time.
The present invention generally relates to various photoreactions, including reactions generally based on triplet-triplet annihilation upconversion. One aspect of the present invention is directed to systems and methods for absorbing energy (e.g., from a photon) in a photo sensitizer, transferring that energy by triplet-triplet energy transfer to an annihilator to produce a higher energy state via upconversion, then transferring that energy to cleave a cleavable or other active moiety, for instance, in order to cause the release of a releasable moiety. The energy may be transferred to the moiety via Forster resonance energy transfer. In some cases, these may be contained within a suitable carrier material, for example, a particle or a micelle. Such systems and methods may be used in a variety of applications, including various biological or physical applications. For example, such systems and methods may be useful for delivering drugs or other releasable moieties to regions of the body which may be affected by too much light, such as the eye. Other aspects of the present invention are generally directed to methods for making or using such systems, kits including such systems, or the like.
Systems and methods for generating customized annotations of a medical record are provided. The system receives a medical record and processes it using a predictive model to identify evidence of a finding. The system then determines whether to have a recall enhancement or validation of a specific finding. Recall enhancement is used to tune or develop the predictive model, while validation is used to rapidly validate the evidence. The source document is provided to the user and feedback is requested. When asking for validation, the system also highlights the evidence already identified and requests the user to indicate if the evidence is valid for a particular finding. If recall enhancement is utilized, the source document is provided and the user is asked to find evidence in the document for a particular finding. The user may then highlight the evidence that supports the finding. The user may also annotate the evidence using free form text.
Background. The Mobility and Vitality Lifestyle Program (MOVE UP) is a behavioral weight-management intervention for improving mobility among community-dwelling older adults. We examined program factors that affect implementation outcomes and participant-level health outcomes. Methods. The MOVE UP program was implemented in the greater Pittsburgh area from January 2015 to June 2019 to improve lower extremity performance in community-dwelling older adults who were overweight or obese. Thirty-two sessions were delivered over 13 months. All sessions were designed to be 1-hour in length, on-site, group-based, and led by trained and supported community health workers (CHWs). Participants completed weekly Lifestyle Logs for self-monitoring of body weight, diet, and physical activity. We evaluated the MOVE UP program using the RE-AIM framework, and collected quantitative data at baseline, 5-, 9-, and 13-months. Multilevel linear regression models assessed the impacts of program factors (site, CHW, and participant characteristics) on implementation outcomes and participant-level health outcomes. Results. Twenty-two CHWs delivered MOVE UP program to 303 participants in 26 cohorts. Participants were similar to the target source population in weight but differed in some demographic characteristics. The program was effective for weight loss and lower extremity function in both intervention and maintenance periods (ps < .01), with an independent effect for Lifestyle Logs submission but not session attendance. Discussion. CHWs were able to deliver a multi-component weight loss intervention effectively in community settings. CHW and site characteristics had independent impacts on participants' adherence. Lifestyle Log submission may be a more potent measure of adherence in weight loss interventions than attendance.
FIELD: medicine. ^ SUBSTANCE: invention refers to medical products and concerns a pharmaceutical composition containing 2,4-dichlorbenzyl alcohol combined with amylmethacresol and used for treatment or prevention of viral infections caused by SARS coronaviruses. The pharmaceutical composition is presented in the liquid acidulous oral form, or acidified sucking or chewing solid dosage form. There is also disclosed application of 2,4-dihclorbenzyl alcohol and amylmethacresol for making a medicinal agent for treatment or prevention of viral infections caused by SARS coronaviruses. ^ EFFECT: invention aims at development of the agent for treatment of viral infections caused by SARS coronaviruses with Urbani phenotype. ^ 9 cl, 9 tbl, 27 ex
The invention relates to the application of Kadsura heteroclite (Roxb.) Craib polysaccharide of Guangdong province for preparing medicaments for preventing and/or treating senile dementia. Kadsura heteroclite (Roxb.) Craib polysaccharide of Guangdong province is extracted and separated from plant Kadsura heteroclite (Roxb.) Craib of Guangdong province. The invention has the advantage that the purpose of the Kadsura heteroclite (Roxb.) Craib polysaccharide of Guangdong province for preparing medicaments for preventing and/or treating senile dementia is developed, with high safety and obvious treating effect. The Kadsura heteroclite (Roxb.) Craib polysaccharide can be taken for long term and can be prepared into various preparations, with abundant raw material source and low cost.
NEW MATERIAL:An enzyme capable of converting big endoserine to endoserine, having optimum pH 7 and being inhibited with EDTA, copper (II) sulfate, copper (II) chloride, Bacitracin, etc. USE:A drug being administered to a patient of hypotension requiring endoserine to produce endoserine from big endoserine. A reagent for searching an endoserine conversion inhibitor. PREPARATION:First, swine brain is homogenized in a buffer solution and the supernatant liquid thereof is centrifuged to give a membrane fraction as precipitate. Then the fraction is homogenized in a solubilizing agent-contaning buffer solution and centrifuged to give the supernatant liquid. Finally, the supernatant liquid is purified by chromatography.
This is a rater- blind, parallel assignment, randomized and active controlled study. The subjects investigated are outpatients or inpatient with schizophrenia from the Chinese Han race. The screening phase lasts for 1 week. The eligible patients enter the next randomized treatment phase. The titration duration is 1 week. After the first week, the patients are administered with a flexible dose regimen. In this study, the effective doses range of seroquel and risperidone are 600-750mg/d and 3-6mg/d respectively and the treatment duration lasts for 6 weeks.

The efficacy and safety of seroquel in the treatment of patients with schizophrenia have been confirmed by multiple double blind studies. This study is designed to evaluate the efficacy and safety of seroquel in the treatment of Chinese Han patients with schizophrenia. Therefore, the single blind and active control design should be selected for this study. The drug titration method and dose are within the range specified in the instruction and patients with schizophrenia are tolerant to the drug in clinical treatment.

The purpose of schizophrenic patient treatment is to improve the core symptoms, prevent suicide and other aggressive behavior, alleviate the side reactions caused by the drug, and recover the life functions of patients. Generally, the treatment in the acute phase lasts for 6 to 8 weeks. In this study, the treatment in the acute phase lasts for 6 weeks.

The rating scales used in this study are standard psychiatric rating scales with good validity and are widely used in the study of antischizophrenia drugs and in the treatment of patients with schizophrenia in China. The PANSS is developed from two early rating scales, namely the brief psychiatric rating scale (BPRS) and the psychiatric rating scale. The high inter-investigator reliability and repeated measurement reliability of these scales have been proved by multiple studies. The clinical global impression (CGI) is a simple but convenient global impression scale. It is applicable to any patients treated and studied by the psychiatric department. The Carlgary depression scale for schizophrenia (CDSS) is used to evaluate the depressive symptoms of patients with schizophrenia. It has good reliability and validity. The abnormal involuntary movement scale (AIMS) is another evaluation tool consisting of 12 items. The AIMS is used to evaluate the abnormal involuntary movements related to antischizophrenia drugs. The AIMS is nearly the most frequently used multi-item rating scale evaluating of tardive dyskinesia. The Simpson and Angus scale (SAS) is also a rating scale commonly used since its release in 1970. The validity of SAS has been verified in the double blind and placebo-controlled study involving two haloperidol doses.
PURPOSE: To obtain a pharmaceutical composition containing a cysteine derivative and/or a cystine derivative, and capable of maintaining and/or reestablishing blood platelet aggregation at close to the normal value. CONSTITUTION: This pharmaceutical composition contains a cysteine (e.g. acetylcysteine), a cystine derivative (e.g. dansylcystine), and/or their salts as an active ingredient in an amount of 30-4000mg, preferably 100-1000 mg. The composition is further suitably compounded with a vitamin B6 vehicle, an emulsifier, a perfume, a preservative, etc., and subsequently prepared into tablets, pills, powders, granules, syrups, suppositories, injections, etc. The daily dose of the composition is 0.1-5 g. It is especially preferable that the composition is used together with a therapeutic method using a medicine causing or probably causing thrombocytopenia or thrombocytopathia as a side effect.
FIELD: medicine, pharmacy. SUBSTANCE: invention proposes an agent for prolonged effect of hypolipidemic medicinal preparation and medicinal composition for reduction of lipids level based on thereof. Agent represents anion-exchange resin without cross-linked intermolecular linkages comprising structural unit of the general formula (I)   with radical values given in the invention claim. Invention provides both the gradual release of medicinal preparations with high stability and synergistic effect with regards to reduction of blood cholesterol level by both components. EFFECT: enhanced effectiveness and valuable medicinal properties of agent. 7 cl, 2 dwg, 1 tbl, 12 ex
The intervention group will receive a Deep Breathing Training and a Compassion Intervention. Deep Breathing Training and Compassion Intervention will be administered once, on two consecutive days, and will last for 30 minutes.
Participants received 1200 mg ASP1948 intravenously, on day 1 of cycle 1 and 2 followed by once every 2 weeks (Q2W) until discontinuation criteria or up to 2 years. Each cycle duration was 14 days.
FIELD: medicine. ^ SUBSTANCE: invention concerns immunology area. Versions of the artificial fused protein consisting of an antibody (or its fragment) and cytokine, fused through a link peptide are offered. The antibody or its fragment is chosen from an antibody 225, 425, KS 1/4, 14.18, anti-CDx-antibody where x has the whole value 1-25. Each of versions of the fused protein has lowered quantity T-epitopes, at least, in the component of the fused protein presented by an antibody, and as consequence, possesses the lowered adjuvanticity, in comparison with an initial molecule. Identification of T-lymphocyte epitopes is performed by the automated calculation of sizes for the binding centres of class II MHC molecules with the subsequent experimental test of the obtained versions of protein for presence of the lowered adjuvanticity. The automated way of T-epitopes calculation is based on use of the Bjom's function modified in such manner that contribution of Van-der-vaals repulsion and lipophilic interaction in pairs between all lipophilic atoms of the chosen segments of the fused protein and a binding groove of a MHC P molecule is taken into account. Also a way of protein construction on the basis of the modified function Bjom's function with the subsequent experimental test of the received versions for presence of the lowered adjuvanticity is revealed, and also application of the fused protein for preparation of a pharmaceutical composition for tumour treatment is in addition considered. ^ EFFECT: invention use allows obtaining the fused proteins with the lowered adjuvanticity and, basically, keeping identical biological activity in comparison with a parent molecule; it can be used in treatment of tumours. ^ 4 cl, 6 dwg, 22 tbl, 19 ex
Use of m-phenylene diamine (I) and/or their salts (II) in agents for oxidative hair treatment. Use of m-phenylene diamine of formula (I) and/or their salts of formula (II) in agents for oxidative hair treatment. R1-R6H, 1-4C alkyl-, mono- or dihydroxyalkyl, phenyl or benzyl; Y : OH, OR, F, Cl, Br, I or COOH; R : 1-4C alkyl, phenyl or benzyl; and X : inorganic or organic anion. Independent claims are also included for: (1) a method for the durable hair shaping comprising: either bringing the hair before and/or after into the desired form, treating with a keratin reduced shaping agent, optionally rinsing, subsequently oxidative post treating with a fixing agent and optionally rinsing again, where is used as fixing agent; and (2) treating the hair first with keratin reduced shaping agent, optionally rinsing the shaping agent after the induction period, subsequently treating (prefixation) the hair with (I) for oxidative hair treatment and then subsequently post treating (post fixation) with a fixing agent based on hydrogen peroxide or bromate. [Image] ACTIVITY : None given. MECHANISM OF ACTION : None given.
The specific research questions are, i) can the implant partially restore vision to an eye with no light perception and ii) what are the safety implications for the ocular and periorbital tissues of the implanted eye? In advanced RP the light detecting photoreceptor cells of the retina degenerate slowly over time, and may eventually lead to blindness. The subretinal implant replaces the degenerate photoreceptor layer and stimulates the residual overlying healthy retinal layers in response to a light stimulus. These signals are then carried on to the brain along the normal visual pathway. Investigators are seeking to recruit six participants who fulfill the eligibility criteria, which include advanced RP with no useful light perception vision in the eye to receive the implant. Participants must be aged between 18 and 70 years old, be highly motivated, and be well enough for a general anaesthetic. The eye must have also had cataract surgery. The project will be conducted at the Oxford Eye Hospital. Those participants selected to receive the implant will be followed for 12 months from the date of surgery. Between week 1 and month 12 there will be at least 7 outpatient clinic visits for a range of visual tests and eye assessments. After 12 months the trial will officially end, however investigators will continue to review all research participants in clinic as would be standard care for a patient with RP. The implant may be removed at any stage e.g. when it ceases to function or at the participant's request.
Participants self-administered 4 actuations (two per nostril) of placebo HFA once daily each morning for 6 weeks (42 days) as double-blind therapy for BDP. During week 6 (days 36-42), participants also took a 10/mg a day prednisone capsule.